Immune checkpoint inhibitors (CPIs) targeting programmed cell death-1 (PD-1), such as nivolumab and pembrolizumab, have demonstrated remarkable efficacy in relapsed or refractory classical Hodgkin lymphoma (cHL) [1–3]. Here, PDCD1 is linked to classic Hodgkin lymphoma.